Life sciences companies have an opportunity to craft a sales approach that resonates with clients, protects against future disruptions and stands out from the competition.
Eduardo Schur
Advertisement
Eduardo Schur is Principal, EY Americas Health Science and Wellness Commercial Strategy Leader.
Articles by Eduardo Schur
While COVID-19 has shifted some of the rules, research reveals that practice changes were already afoot for market newcomers.
While COVID-19 has shifted the rules of the healthcare industry, research shows there was already progress on changes being made for how pharma companies are launching products.
As the market for specialty and generic products continues to become more competitive and pricing pressures increase, the 505(b)(2) pathway may allow companies more options to diversify their portfolios.
Advertisement
Latest Updated Articles
- New Standards for First-to-Launch Players
Published: September 14th 2020 | Updated:
505(b)(2): A Pathway to Competitiveness Through Innovation for Specialty and Generic CompaniesPublished: December 4th 2019 | Updated:
- Research Reveals New Launch Standards for First-to-Launch Pharma and Biotech Companies in the U.S.
Published: June 26th 2020 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Libtayo for Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma
2
The Situation We Faced: The Development and Commercialization of MariTide
3
Most Favored Nation Order: Legal Battles, Market Shifts, and the Future of Drug Pricing Reform
4
Novo Nordisk Enters $4.7 Billion Definitive Agreement with Akero Therapeutics
5
